No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

No­vo Nordisk’s semaglu­tide has hit a pair of pri­ma­ry end­points in a late-stage test in pa­tients with a trio of car­diometa­bol­ic con­di­tions, bol­ster­ing the com­pa­ny’s ef­forts to ex­pand its ter­ri­to­ry in obe­si­ty and type 2 di­a­betes to oth­er, re­lat­ed in­di­ca­tions.

Show­ing that semaglu­tide can im­prove car­dio­vas­cu­lar out­comes can help No­vo fur­ther boost the drug’s re­im­burse­ment prospects. In March, the block­buster drug won FDA ap­proval to re­duce the risk of car­dio­vas­cu­lar death, heart at­tack and stroke in obese or over­weight heart dis­ease pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.